Medindia
Medindia LOGIN REGISTER
Advertisement

BayBio: Europe's Leading Biotechnology Market Presents Opportunities to US Companies

Wednesday, April 7, 2010 Press Release
Advertisement
SAN FRANCISCO, April 6, 2010 Germany is ranked number onein exporting research-intensive goods. This level of innovation drives theworld's second largest market for biotechnology after the United States.Germany Trade & Invest will have representatives at this year's BayBio 2010conference on April 7 in San Francisco, California, to highlightopportunities for American companies in Germany.
Advertisement

There are more companies operating in the biotech and biomedical sectorshere than in any other country in Europe. Revenue in this industry has grownover 40 percent between 2005 and 2009 and promises to expand in the comingyears.
Advertisement

A driving force of this industry is the commitment to research anddevelopment. Dedicated biotechnology companies annually invest nearly EUR 1billion. This industry contributed strongly to the recently announcedfindings by the German Institute for Economic Research (DIW), which concludedthat Germany had the largest proportion of research-intensive goods andservices in the world in 2007. In addition, Germany is the world's leadingexporter of research-intensive goods, making it an ideal site forbiotechnology companies to commercialize cutting-edge technologies.

Eastern Germany, especially the capital region Berlin-Brandenburg, hasbecome a hotbed for the biotechnology industry. This cluster makes up almosthalf of all biotechnology companies in Eastern Germany. Nationwide, hundredsof companies work together with research institutes and partners to boostinnovation capacity.

The integration of biotechnology clusters further improves the country'sattractiveness as an investment location. Research institutes and companieslarge and small can utilize the cluster structure to share ideas, innovatewith partners and quickly bring new products to market.

Germany Trade & Invest will be leading the panel "Open Innovation: GlobalStrategies" as a forum to showcase the leading approaches to integrating theinnovation process from research to commercialization. Representatives fromMologen AG, a leader in the Berlin-Brandenburg biotechnology cluster in thefield of developing DNA-based drugs, will discuss the advantages of doingbusiness in Germany, from the highly developed innovation infrastructure tothe wide range of public and private financing options. Other major players,including Bayer HealthCare Pharmaceuticals, Theralive, and Omicia, Inc. willaddress the role of international R&D cooperation and Germany's role instrengthening partnerships.

Germany Trade & Invest is the foreign trade and inward investmentpromotion agency of the Federal Republic of Germany. The organization advisesforeign companies looking to expand their business activities to the Germanmarket. It provides information on foreign trade to German companies thatseek to enter foreign markets.Germany Trade & Invest Eva Henkel Email: [email protected] T: +49(0)30-200099-173 F: +49(0)30-200099-111

SOURCE Germany Trade and Invest
Sponsored Post and Backlink Submission


This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close